Skip to main content

BOSTON ( TheStreet) -- Oncothyreon (ONTY) was the runaway stock-performance winner of ASCO '15.

Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology annual meeting. Oncothyreon's presentation of early-stage data on breast cancer drug ONT-380 was well received but investors were probably more enamored with the company's relatively low valuation.

I chose this 16-day trading period to track stock performance because it begins with the public release of ASCO research abstracts on May 13 and ends the day after the meeting concluded.

Puma Biotech (PBYI) - Get Puma Biotechnology, Inc. Report was the worst-performing biotech and drug stock during the ASCO period, falling 28% due to the underwhelming efficacy and high rate of side effects seen with the company's breast cancer drug neratinib

IgnytaRXDX and ImmunoGen (IMGN) - Get ImmunoGen, Inc. Report were the other big ASCO winners, returning 93% and 61%, respectively. 

Image placeholder title

Turning to Big Pharma, it's fair to say Bristol-Myers Squibb (BMY) - Get Bristol-Myers Squibb Company Report received the most media coverage for its cancer immunotherapy drugs Opdivo and Yervoy, but some of the data presented didn't sit well with investors because the stock lost almost 3% during the ASCO performance period. 

TheStreet Recommends

None of the Big Pharma stocks moved all that much, but Abbvie (ABBV) - Get AbbVie, Inc. Report and Roche (RHHBY) emerged as winners with stocks each moving 3% higher.

Image placeholder title

This year's ASCO meeting didn't feature much new data from the CAR-T stocks, but Juno Therapeutics (JUNO) had enough to move the stock 25% higher.

Image placeholder title

Among mid- and large-cap biotech stocks, Seattle Genetics came out on top with a 14% return. 

Image placeholder title

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.